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Abstract: 
Currently no pharmacogenomics-based criteria exist to guide clinicians in identifying individuals 
who are at risk of hearing loss from cisplatin-based chemotherapy. This review summarizes findings 
from pharmacogenomic studies that report genetic polymorphisms associated with cisplatin-induced 
hearing loss and aims to (1) provide up-to-date information on new developments in the field; (2) 
provide recommendations for the use of pharmacogenetic testing in the prevention, assessment and 
management of cisplatin-induced hearing loss in children and adults; and (3) identify knowledge 
gaps to direct and prioritize future research. These practice recommendations for pharmacogenetic 
testing in the context of cisplatin-induced hearing loss reflect a review and evaluation of recent 
literature and are designed to assist clinicians in providing optimal clinical care for patients 
receiving cisplatin based chemotherapy.  
Keywords: Cisplatin, ototoxicity, hearing loss, pharmacogenetic testing, clinical practice 
recommendations 
 
 
1. INTRODUCTION 
1.1 Cisplatin 
Cisplatin (PLATINOL®) is a widely used chemotherapeutic agent as a standard treatment for a 
variety of solid tumours.  It is one of the most effective chemotherapeutic agents for children and 
has contributed to the dramatic increase in survival from many solid tumors including 
neuroblastoma, hepatoblastoma, brain tumors, osteosarcoma, and germ cell tumors.  In fact, 
cisplatin has shown efficacy in standard risk hepatoblastoma, such that it can be used as 
monotherapy with an over 80% 3-year event-free survival1. Cisplatin is also used to treat a variety 
of adult cancers including ovarian, gastrointestinal, testicular, lung, and head and neck tumours2,3. A 
major complication that limits the clinical use of cisplatin is the risk of drug-induced ototoxicity that 
can result in life-long disability4.  Cisplatin ototoxicity manifests as permanent, bilateral hearing 
loss which affects 10-25% of adults and 26 -90% of children5-8.  In particular, even mild hearing 
loss in children can significantly influence speech and language development, social-emotional 
development and increase the risk of learning difficulties9.   
 
1.2 Clinical presentation and assessment of cisplatin-induced hearing loss 
In patients receiving the same dose of cisplatin, the inter-individual variability of ototoxicity is 
profound, ranging from no hearing loss to high frequency hearing loss and progresses to severe 
hearing impairment in the speech frequencies10.  Pure-tone audiometry measurements are used to 
determine the degree of hearing loss in patients, which is reported as a numeric grade. Several 
different grading criteria for ototoxicity have been developed over the years.  The most commonly 
used methods are the Common Terminology Criteria for Adverse Events 4.0 (CTCAE)_ENREF_15,11  
and the Brock scale6 (Table 1).  However, various other grading schemes exist such as the Muenster 
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classification for early detection of hearing loss12, Chang scale13 and the recently developed 
International Society of Pediatric Oncology (SIOP) Boston Ototoxicity Grading Scale14. In standard 
treatment protocols, the occurrence of moderate to severe cisplatin ototoxicity leads to dose 
reduction or the termination of cisplatin treatment, which may affect survival rates15. 
1.3 Mechanisms influencing outcomes 
There is a significant amount of evidence suggesting that the major mechanism of action of cisplatin 
is the formation of intra-strand and inter-strand crosslinks with DNA.  This activates multiple signal 
transduction pathways associated with cellular processes including cell-cycle arrest, DNA repair, 
and programmed cell death16.  Platinum cochlear toxicity is thought to occur due to interference 
with signal transduction in the cochlea.  Evidence indicates that cisplatin damage by apoptosis 
occurs at three sites in the cochlea: the outer hair cells in the organ of Corti, the spiral ganglion and 
the stria vascularis17. 
 
Cisplatin-induced hearing loss is difficult to treat, primarily as the mechanisms involved in this 
process are not well understood.  Several lines of evidence suggest that the generation of reactive 
oxygen species (ROS) are involved in the toxicity associated with cisplatin therapy18.  ROS-
mediated damage occurs as a consequence of antioxidant depletion and increased lipid peroxidation 
in the cochlea.  The increase in ROS has been reported to lead to morphological and functional 
changes in the organ of Corti19.  The production of ROS changes acoustic transduction by 
modulating the outer hair cell motility in the organ of Corti resulting in cell death20.  
1.4 Risk factors for cisplatin-induced ototoxicity 
Clinical risk factors are known to influence the susceptibility of cisplatin-induced ototoxicity. These 
include cumulative cisplatin dose and dosing schedule, patient age at treatment, pre-existing hearing 
impairment, concomitant use of aminoglycosides and cranial irradiation (Box 1)21. It is now 
recognized that there is significant variability in hearing loss between individual patients receiving 
similar cumulative doses and application schedules of cisplatin suggesting that clinical risk factors 
alone are insufficient predictors of safety15.   
 
Genetic variation in the genes involved in the biotransformation, transport, and targets of drugs have 
been recognized to influence patient drug response and susceptibility to adverse drug events, 
including ototoxicity22. Specific variations in the DNA sequence (single nucleotide polymorphisms 
(SNPs), insertions, deletions) that alter gene expression or protein function may thus influence the 
susceptibility to drug-induced toxicity and could facilitate the stratification of patients based on 
toxicity risk. To date, studies have implicated multiple genes in the susceptibility to cisplatin-
induced hearing loss. Specifically, genetic variants in methyltransferases (TPMT, COMT), 
transporters (ABCC3, CTR1), glutathione-S-transferases (GSTs), megalin (LRP2) and DNA repair 
genes (XPC) have been associated with cisplatin-induced ototoxicity. _ENREF_11_ENREF_30Evidence 
regarding associations of variation in these genes was reviewed and is summarized below (Section 
2), with a more detailed summary provided in the Supplemental Material 
(http://links.lww.com/TDM/A140).    
 
1.5 Scope and purpose 
Currently no pharmacogenomics-based criteria exist to guide clinicians in identifying individuals 
who are at risk of cisplatin-induced hearing loss.  This review is intended to (1) summarize and 
evaluate recent literature from pharmacogenomic studies that report associations of genetic 
polymorphisms with cisplatin-induced hearing loss to provide up to date information on new 
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developments in the field; (2) provide recommendations for the use of pharmacogenetic testing in 
the prevention, assessment and management of cisplatin-induced hearing loss in children and adults; 
and (3) identify gaps in knowledge to direct and prioritize future research. These practice 
recommendations for pharmacogenetic testing in the context of cisplatin-induced hearing loss are 
designed to assist clinicians in providing optimal clinical care for patients receiving cisplatin based 
chemotherapy.  
Specifically, recommendations are provided to address the following questions: 
1. Should genetic testing be performed in patients with an indication for cisplatin therapy, in 
order to reduce the occurrence of cisplatin-induced hearing loss? What genes and gene 
variants should be tested? 
2. Which patients should be tested and when? 
3. How should patients undergoing cisplatin therapy be managed based on their genetic test 
results? 
 
2. SUMMARY OF SUPPORTING EVIDENCE 
2.1 Methlytransferase genes (TPMT and COMT) 
Genetic polymorphisms in TPMT are implicated in the susceptibility to cisplatin-induced hearing 
loss in children (see detailed evidence summary in the supplementary materials and Supplementary 
Table S1, http://links.lww.com/TDM/A140). Specifically, TPMT variants rs12201199, rs1800460 
and rs1142345 have been associated with ototoxicity in three independent pediatric cohorts15,23. 
These risk variants include the TPMT*3B, *3C and *3A (*3B + *3C) loss of function alleles, which 
lead to rapid degradation of the TPMT proteins24. In a cohort of 317 children, 43 (91.5%) carriers of 
the TPMT risk variant developed hearing loss compared to only four carriers (8.5%) patients 
without hearing loss (Table S10), conferring a specificity of 96.8% and sensitivity of 22.3%23. Three 
studies differing from the previous reports in patient cohorts and the treatment regimens used, 
reported non-significant associations between the TPMT variants and cisplatin-induced ototoxicity, 
however similar trends were observed in sub-cohorts of similarly treated patients25-27. Thus, 
evidence suggests an association of TPMT variants with cisplatin-induced hearing loss but with 
limitations in generalizability and the number of studies available (+++ evidence; Table 2). 
 
Variants in COMT (rs9332377 and rs4646316) have shown similar trends of associations in four 
independent pediatric cohorts (Table S1)15,23,26. These associations reached statistical significance 
only in two of the four cohorts while two additional studies have also reported effect sizes in the 
opposite direction25,27. Taken together, the evidence supporting the role of COMT is encouraging 
but requires further replication with specific attention to using comparable patient cohorts (++ 
evidence). COMT and TPMT enzymes utilize the same substrate, S-adenosylmethionine, and 
variants of these genes are hypothesized to alter cisplatin cytotoxicity by modulating cross-linking 
with purines in DNA15. Furthermore, S-adenosylmethionine has been demonstrated to increase 
cisplatin nephrotoxicity in rats28.  
 
2.2 Cisplatin transporters (ABCC3, CTR1) 
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To date, two studies reported associations of a synonymous variant in ABCC3 (rs1051640) with 
cisplatin-induced hearing loss in pediatric patients (Table S2)15,23. _ENREF_31ABCC3 is a transporter 
that mediates the efflux of organic anions, xenobiotics and glutathione S-conjugates, including 
glutathione S-conjugated cisplatin29,30. Reduced activity of ABCC3 may thus affect cisplatin 
detoxification through reduced transport of toxic compounds out of the cell.  Evidence supporting a 
role of ABCC3 in cisplatin-induced ototoxicity is promising (++ evidence), but this association 
requires further replication to strengthen the current evidence. Furthermore, the functional 
consequences of the synonymous rs1051640 variant has yet to be identified and should be 
determined.  
 
Copper transporter proteins (CTRs) are major plasma membrane transporters that mediate both 
cisplatin uptake and export at the plasma membrane31. A study in non-small cell lung cancer 
patients treated with cisplatin reported a variant in CTR1 (rs1098169) associated with increased 
ototoxicity in adults32. Independent replication and investigations in pediatric cohorts are necessary 
to extend this promising finding (++ evidence).  
 
2.3 Gluthathione S-Transferases (GSTs) 
One of the mechanisms of cisplatin detoxification is the conjugation of the active platinum 
metabolite with glutathione by glutathione s-transferases (GSTs)33,34. _ENREF_42Several studies 
have therefore examined polymorphisms in GST genes (GSTM, GSTP, GSTT) in the context of 
cisplatin-induced hearing loss (Tables S3-S6)15,35-41. 
 
One study reported a higher frequency of the GSTM3*B allele in pediatric patients with normal 
hearing compared to patients with ototoxicity (Table S3)35. _ENREF_50However, a second study 
investigating GST polymorphisms in ovarian cancer patients could not replicate this association38 (+ 
evidence). In a study by Oldenburg et al., GSTP1 rs1965 was significantly associated with cisplatin-
induced ototoxicity in adult testicular cancer survivors (Table S4)36. However, this association did 
not achieve statistical significance in an extended patient cohort37. Rednam et al. reported an 
opposite effect of GSTP1 rs1965 on cisplatin-induced hearing loss in a pediatric medulloblastoma 
cohort42. Furthermore, five studies (4 pediatric, 1 adult) reported no significant association of 
GSTP1 with hearing loss15,23,35,37,38. Overall, evidence regarding an effect of GSTP1 rs1695 on 
ototoxicity is thus inconsistent (Table S4) (+ evidence). Finally, associations with cisplatin-induced 
ototoxicity have also been reported for GSTM1 (Table S5)36,37 and GSTT1 (Table S6)39. However, 
numerous other studies have not replicated these associations15,35-38,41,42 (+ evidence). 
 
 _ENREF_47 
2.4 Megalin (LRP2) 
Two non-synonymous variants (rs2075252, rs2228171) in LRP2 have been examined in four 
different studies of children treated with cisplatin (Table S7)15,23,39,43. Riedemann et al. reported a 
significant association between rs2075252 and cisplatin-induced ototoxicity43. A nonsignificant 
trend for an association for rs2228171 was also identified. Conversely, Choeyprasert et al. found 
that rs2228171 was negatively associated with cisplatin-induced hearing loss with no association for 
rs207525239. In two additional large studies, both variants were not associated with cisplatin-
induced hearing loss in children15,23. Overall, given these inconsistent findings, further evidence is 
required to determine the relevance of rs2075252 and rs2228171 for cisplatin-induced ototoxicity (+ 
evidence).  
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2.5 DNA repair genes  
To date, the association of genetic variants in the DNA repair pathway with cisplatin-induced 
ototoxicity has been investigated in three studies (Table S8). A small study of pediatric and adult 
patients reported a significant association of a non-synonymous SNP in XPC rs2228001 with 
hearing loss44. However, this finding has yet to be replicated, with a lack of association reported in a 
larger pediatric cohort of 317 patients23. Another independent study also did not observe any 
association of variants in ERCC1, XPD and XRCC1 with cisplatin ototoxicity (Table S8)38. Given 
the lack of replication, it is difficult to draw any conclusions about an effect of rs2228001 on 
cisplatin ototoxicity (+ evidence). 
 
 
2.6 Genes associated with hereditary or age-related deafness 
Variants in GJB2, SLC26A4 and mitochondrial (mtDNA) polymorphisms in MTRNR1, MTTL1 and 
MTTS1 have been associated with aminoglycoside-mediated ototoxicity and progressive 
nonsyndromic high frequency hearing loss. Two studies investigating the role of mtDNA 
polymorphisms for cisplatin-induced hearing loss in children showed no evidence for a contribution 
of these variants to the susceptibility to cisplatin-induced hearing loss (Table S9)45,46. Therefore, 
there is currently no evidence to suggest an association of genes involved in hereditary deafness 
with cisplatin-induced ototoxicity (+ evidence). One study examining variants in otospiralin (Otos), 
an inner ear protein implicated with age-related hearing deterioration, reported a significant 
association between a protective haplotype and cisplatin-induced ototoxicity (Table S9)47. Although 
the evidence is limited at this time, these findings provide the basis for larger replication studies to 
validate this genetic association (++ evidence). 
 
3. CLINICAL PRACTICE RECOMMENDATIONS 
Recommendations and considerations 
3.1 Should genetic testing be performed in patients prior to initiation of cisplatin, in order 
to reduce the occurrence of cisplatin-induced hearing loss? What genes and gene variants 
should be tested? 
There are genetic variants that should be tested in patients prior to initiation of cisplatin therapy to 
alert physicians and patients/families about the increased risk of cisplatin-induced hearing loss in 
susceptible patients.  
 
TPMT functional variants (A): 
Recommendation: We recommend pharmacogenetic testing for the associated functional 
TPMT variants (*3A, *3B, *3C) and the known, relatively common, and functionally inactive 
TPMT *2 variant in pediatric patients to receive cisplatin (level A – strong recommendation; 
Table 3).  
Considerations: In over 95% of Caucasian and Asian patients, low TPMT activity is explained by 
three alleles (TPMT *2, *3B, and *3C)48. In African populations, *3C and *2 are also common. All 
of these variants demonstrate reduced in vitro enzyme activity49. Around 10% of the population 
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carry one of these TPMT risk variants, which account for approximately 25% of patients with 
ototoxicity (accounting for 27.9%, 21.9%, and 24% of ototoxicity in 3 independent patient 
cohorts)15,23. Thus, the TPMT risk variants do not account for all cases of cisplatin ototoxicity. 
However, the high positive predictive value (92%) of the TPMT variants indicates that a vast 
majority of patients who carry these variants develop hearing loss. The importance of identifying 
risk of hearing loss in children and the potential management strategies warrant a strong 
recommendation that children should be genotyped for risk variants in the TPMT gene. If 
genotyping is unavailable or impractical, TPMT phenotyping may be an alternative method to 
identify patients with low enzyme activity, even though this has not been investigated in any studies 
yet.  
 
 
 
Variants in COMT, ABCC3, CTR1, GSTs, LRP2, DNA repair and deafness genes (C): 
Testing for variants in COMT, ABCC3, CTR1, GSTs, LRP2, DNA repair genes and genes associated 
with deafness is currently not recommended for clinical use (level C – optional recommendation). 
Further research is needed to determine the optimal strategy for the utilization of genotype 
information for these genes in therapeutic decision-making and strengthen the evidence supporting 
the genetic associations (see section 4).  
 
3.2 Which patients should be tested and when? 
3.2.1. Pediatric patients 
Recommendation: Studies of pediatric oncology patients suggest that all children undergoing 
cisplatin therapy should be tested for genetic variants in TPMT (A). Ideally, children should be 
tested prior to the initiation of therapy to enable optimal consideration of therapeutic options in the 
context of genetic test results. However, the genetic test may also provide valuable information for 
patients who are already undergoing treatment, e.g. to guide decision-making on post-treatment 
follow-up. 
Considerations: The current standard of care in pediatric oncology for treatment with cisplatin is to 
monitor hearing with audiograms before further doses of cisplatin are given. Patients who develop 
clinically significant hearing loss generally have a 50% reduction of subsequent doses of cisplatin50. 
Further hearing loss often results in complete elimination of cisplatin from the treatment plan. The 
use of pharmacogenetic information to define a patient at high risk of hearing loss can thus be used 
to consider potential dose reductions earlier in treatment.  This approach is not much different than a 
dose reduction after toxicity onset, but allows the clinician to consider making this change sooner in 
the treatment plan.  There are exceptions to this rule, such as cisplatin used in the treatment of 
hepatoblastoma, where no dose reduction is suggested at any point, given the critical role of 
cisplatin with regards to cure51,52.  An important area of future investigation is how much sooner 
than actual toxicity (i.e., hearing loss) potential dose changes can be made without compromising 
cure rates.  
3.2.2. Adult patients 
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Recommendation: Currently, the impact of the genetic variants recommended for testing in 
children is unknown in adult patients. At this point, genetic testing to identify patients at risk for 
cisplatin-induced hearing loss is NOT recommended in adult patients (C). This guideline will be 
updated to incorporate recommendations regarding genetic testing in adults as more studies become 
available. In the meantime, it is recommended that all adult patients to be treated with cisplatin 
receive audiometric testing before treatment initiation and at least one post-treatment follow-
up to monitor the occurrence of cisplatin-induced hearing loss.   
 
 
3.3 How should patients undergoing cisplatin therapy be managed based on their genetic 
test results? 
The current endpoint for clinical intervention in cisplatin therapy is moderate to severe, irreversible 
hearing loss. By knowing in whom cisplatin hearing loss is likely to occur, clinicians have the 
possibility to consider altering therapy or monitoring before hearing loss occurs. Importantly, 
information gained from genetic testing should be used in the context of the unique circumstances 
of each individual patient to evaluate optimal treatment strategies, taking into consideration the 
balance between risk of toxicity and potential impact of management strategies on anti-tumour 
efficacy of therapy and cancer survival. Post-test treatment options will vary based on cancer type 
and should fall within the current guidelines and standards for cancer care. In the future, additional 
studies should be conducted to investigate the potential of individualized interventions based upon a 
patient’s cisplatin pharmacogenetic risk factors.  
 
In Table 4, a breakdown of the risk genotypes for cisplatin ototoxicity and their interpretations is 
provided. Based on the genetic variants currently recommended for pharmacogenetic testing, 
patients who carry ANY nonfunctional TPMT variant (*3A, *3B, *3C, *2) should be considered 
at high risk of cisplatin-induced hearing loss. In these patients, the following management options 
are recommended:  
 
(1) Physicians are encouraged to consider the use of otoprotectants (i.e. amifostine, sodium 
thiosulfate) if the patient’s tumour type is one for which otoprotectants may be effective to prevent 
cisplatin-induced ototoxicity without adversely affecting antitumour activity (C; see section 2.9 in 
the supplementary materials, http://links.lww.com/TDM/A140, for a discussion of evidence on the 
effectiveness of otoprotectants). Current standard of care guidelines for the respective tumour types 
should be consulted to determine if otoprotectants are an option. 
 
(2) Alternative treatments may be prescribed when they have demonstrated equal efficacy, 
manageable and acceptable toxicity, less ototoxicity, and are considered options within the current 
standards of care (C).  For example, studies have reported similar outcomes in pediatric germ cell 
tumour patients treated using carboplatin, etoposide and bleomycin compared to treatment with 
cisplatin, etoposide and bleomycin but with less ototoxicity53,54 and treatment with carboplatin, 
etoposide and bleomycin has been suggested as an alternative treatment in young children55. A 
possible role for carboplatin has also been suggested in the treatment of neuroblastoma, where one 
study reported similar survival between patients receiving cisplatin therapy and patients receiving 
partial substitution of cisplatin therapy with carboplatin56.  
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In adult patients, the substitution to carboplatin is not recommended as it is found to be inferior to 
cisplatin in therapeutic effectiveness for several tumours, such as testicular, bladder, head and neck 
cancers57. Oxaliplatin however, has been investigated as an alternative to cisplatin in some tumour 
types. For example, oxaliplatin-based regimens have been recommended as an alternative to 
cisplatin-based therapy for the treatment of advanced gastric cancer58. Studies have also reported 
comparable outcomes to cisplatin-based therapy with reduced toxicity for advanced non-small-cell 
lung cancer 59.  
Considerations: Several factors must be considered when considering alternative treatments in 
patients at high risk of cisplatin-induced ototoxicity. These include goals of treatment, patient and 
physician preference, and socioeconomic considerations. For instance, the margin for acceptable 
toxicity risk may be much lower for treatments that are merely palliative in nature versus those with 
curative intent. In addition, patient preference may play an important role in the decision to use an 
alternative treatment. For example, a professional musician may not wish to risk any level of 
ototoxicity. This lowered margin for acceptable risk also holds true in the situation where 
alternative, equally effective treatments are available, albeit at an increased financial or clinical cost. 
(3) Where appropriate, physicians are encouraged to increase monitoring in high-risk patients (C).  
In these cases, increased monitoring may lead to earlier detection of hearing loss and allow 
physicians to implement alternative methods of treatment earlier to prevent further damage, such as 
the above recommendations. Similarly, management of hearing loss (speech therapy, hearing aids) 
may be initiated earlier to facilitate language development in children and minimize learning and 
social difficulties associated with hearing loss.  
(4) High risk patients should be encouraged to receive more frequent follow-up audiometric hearing 
tests after treatment has ended (C). These are usually offered as standard care by medical service 
plans.  
Considerations: Current Children’s Oncology Group (COG) recommendations for audiological 
screening for children treated with cisplatin suggest that all subjects have full hearing testing at the 
conclusion of their treatment or at the transition to a survivorship clinic.  No further hearing testing 
at a later time point is recommended by the COG except in situations where there are specific 
clinical concerns. Similarly, there are currently no guidelines as to when audiogram hearing tests 
should be conducted post therapy. However, there is evidence that cisplatin can be isolated in the 
inner ear 20 years post therapy60. Moreover, there are recent reports of late onset hearing loss 
occurring after treatment with cisplatin61. Therefore, additional and long-term follow-up 
investigating hearing outcomes should be considered in high-risk patients. In particular, follow-up 
tests may be missed by patients living in remote areas, until severe hearing loss occurs, at which 
time there are no preventative options to consider. The optimal frequency and duration of 
audiometric hearing tests post therapy remains unknown and requires further study. 
 
 
4. FUTURE DIRECTIONS  
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4.1 Standardized clinical classification of cisplatin-induced hearing loss 
Currently, a major challenge in assessing cisplatin-induced ototoxicity is the lack of a standardized 
grading scheme of patient hearing in all studies. Several different grading criteria are available, 
which are inconsistently used to phenotype patients. This can lead to discrepancies in research 
findings and difficulties comparing results between studies as differences in the classification of 
patients can significantly alter the results of an association study. For clinical application, it is 
essential to validate genetic findings in independent patient cohorts for assessment of reproducibility 
and generalizability. A standardized phenotyping method would significantly facilitate accurate 
replication studies, and enable cross-study comparison of research findings.  
 
4.2 Analyses of associated variants in additional patient populations  
It is important to recognize that children and adults metabolize, distribute and eliminate certain 
drugs differently, which could result in different genetic variants being responsible for cisplatin-
induced toxicity. The importance of genetic risk variants may also differ between treatments for 
different malignancies due to differences in treatment protocols.  However, due to limited sample 
sizes it has been difficult to carry out subgroup analyses to determine whether genetic associations 
are specific to certain treatment protocols. For example, based on a recent study25, a possible impact 
of concomitant amifostine or craniospinal irradiation on the association of TPMT and COMT 
variants with cisplatin-induced hearing loss in children requires further investigation to ascertain the 
impact of these confounding factors on genetic associations. In addition, a majority of studies have 
been carried out in populations of European ancestry. Whether these same genetic variants are also 
associated in different patient populations with other ancestries still needs to be investigated. Due to 
these potential differences between patient populations, the genetic testing recommendations 
provided here currently apply only for cisplatin therapy in children. Studies in adult patients are 
underway and are expected to become available in the near future to provide information on the 
relevance of these gene variants in the adult population. 
_ENREF_52 
4.3 Predictive modeling to combine genetic and clinical risk factors 
Multi-marker predictive models combine the effects of several genes and/or clinical factors into one 
predicted outcome. Pussegoda et al. developed a predictive model that includes the COMT and 
ABCC3 variants, along with TPMT variants23. In this model, based on currently available evidence, 
the COMT and ABCC3 variants do not contribute to the prediction of patients at high risk of 
cisplatin-induced ototoxicity (supplementary materials, http://links.lww.com/TDM/A140). Instead, 
the model suggests that the COMT and ABCC3 genotypes may enable the stratification of patients 
between intermediate and lower risk. However, additional research is needed on how to optimally 
incorporate genetic information from these genes to improve the prediction of low versus 
intermediate risk patients, and on how to optimally adjust therapy in these risk groups. For example, 
whether patients at low risk need less intensive monitoring or could be treated with higher doses to 
improve survival without increasing cisplatin-induced hearing loss requires further investigation. 
Furthermore, other genetic variants that demonstrate reproducible associations should also be 
incorporated into risk prediction models in order to assess their optimal use for patient stratification. 
In addition to genetic factors, clinical factors affecting the risk of ototoxicity should be included in 
such a predictive model. The evidence of clinical risk factors in cisplatin-induced deafness has not 
been systematically reviewed in this guideline and is therefore not included in current 
recommendations. However, the combined inclusion of clinical and genetic risk factors may 
improve the stratification of patients at high risk compared to using genetic risk factors alone. 
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Ultimately, by including both clinical and genetic factors into a model it may be possible to move to 
a simple risk score-based model to classify patients as high, intermediate and low risk. 
 
4.5 Prospective studies, alternative treatments, cost effectiveness 
All genetic association studies for cisplatin-induced ototoxicity thus far have been retrospective. 
The recommendations at this time are therefore based on retrospective evidence of clinical validity. 
It will be important to prospectively investigate the clinical utility of these tests in the future. In 
addition, prospective studies are needed to optimize the real-world clinical utility (effectiveness) of 
predictive pharmacogenetic testing by evaluating additional therapeutic options in high-risk patients 
in the context of therapeutic effectiveness and patient survival. In particular, further studies are 
needed to investigate the use of alternative medications (e.g. carboplatin, oxaliplatin), as well as 
alternative administration routes (e.g. continuous infusion vs. bolus) of cisplatin in high-risk 
patients. For example, even though evidence is ambiguous regarding the overall risk of hearing loss 
for continuous infusion vs. bolus administration of cisplatin62, it is possible that a different 
administration route provides an advantage specifically for patients with a genetically increased risk 
for ototoxicity.  
 
Similarly, it is important to conduct prospective trials to confirm whether otoprotective agents are 
effective in protecting against ototoxicity in children treated with cisplatin and other platinum based 
chemotherapy agents. Future trials should assess large patient cohorts stratified by genetic 
ototoxicity risk factors for outcomes including ototoxcity, anti-tumour efficacy, adverse effects and 
quality of life.  A few phase III trials are currently ongoing in pediatric patients to assess whether 
sodium thiosulfate (STS) and amifostine can prevent hearing loss in children while maintaining 
efficacy of chemotherapy. Additional large clinical trials with amifostine, STS and other 
otoprotective agents such as N-acetyl cysteine (NAC) and D-methionine should be carried out in 
both adults and children with a variety of different tumour types to strengthen evidence and enable 
conclusions about their effectiveness. 
 
The provided recommendations only include clinical actions that fall within current standards of 
care, such as increased monitoring and alternative chemotherapy drugs that are within standard 
treatment protocols. In the future, new evidence may support the use of alternative cisplatin dosing 
or new otoprotective strategies. The recommendations in this guideline are thus considered iterative, 
and should continue to build upon new evidence as it is generated. Updates of recommendations are 
planned on a regular basis to incorporate new evidence. Finally, as genetic testing for cisplatin-
induced hearing loss is used more frequently, an evaluation of the cost-effectiveness of genetic 
testing will become increasingly important and should be performed. 
 
 
 
 
 
5. METHODS 
The same literature review, evidence appraisal, and recommendation development process was 
followed as described previously63,64. In brief, a standard guideline development process was 
followed, in accordance with the quality criteria suggested by the Appraisal of Guidelines Research 
and Evaluation Enterprise (AGREE)65. Following a systematic literature search, critical appraisal of 
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evidence was performed (Table 2), with specific considerations for quality and number of studies, 
consistency of results and magnitude of the effect. Recommendations were developed during a 
meeting of guideline development group members, with each recommendation assigned a level of 
strength, based upon the robustness of the underlying evidence, the balance between benefits and 
risks of genetic testing and genotype-guided treatment, as well as the likelihood of variability in a 
patient’s values and preferences (Table 3). Internal and external review by development group 
members, subject experts and members of the intended target audience was performed. A detailed 
description of the literature search strategy is provided in the Supplementary Materials 
(http://links.lww.com/TDM/A140) along with further details on the intended target audience and 
scope of this document, and the recommendation development group. 
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Box 1. Clinical risk factors for cisplatin-induced ototoxicity  
• Higher cisplatin cumulative dose and bolus administration of cisplatin dose62, 69.  Total dose 
also associated with severity; patients at risk of developing hearing loss in the speech 
frequencies when doses exceed 400 mg/m270. 
• Younger age at time of treatment, patients less than 5 years of age have 20 times higher risk 
compared to similarly treated older patients71. Age reported to have inverse relationship with 
hearing loss severity72. 
• Aminoglycoside antibiotics share similar toxicity profile with cisplatin, causing 
nephrototoxicity, neuropathy and ototoxicity73. 
• Cranial irradiation can cause irreversible hearing loss independently and with greater effect in 
combination with cisplatin74, 75. 
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Table 1: Criteria used to determine the grade of cisplatin-induced hearing loss in patients 
 
Grading 
Scheme 
 
 
Grade 0 
Normal Hearing 
 
Grade 1 
Mild Hearing Loss 
 
Grade 2 
Moderate Hearing Loss 
 
Grade 3 
Severe Hearing Loss 
 
Grade 4 
Severe Hearing Loss 
 
CTCAE Criteria 
4.0315  
 
<20 dB hearing 
loss at all 
frequencies 
 
Hearing loss of ≥ 20 dB 
at 8 kHz 
 
Hearing loss of ≥20 dB at 4 - 
8 kHz 
 
Hearing loss of ≥20 dB 
at 2 - 8 kHz 
 
Hearing loss of ≥ 40 dB 
 at 1 - 8 kHz  
 
Brock Criteria6  
< 40 dB hearing 
loss at all 
frequencies 
Hearing loss of ≥ 40 dB 
at 8 kHz 
Hearing loss of ≥40 dB at 4 
kHz and above 
Hearing loss of ≥40 dB 
at 2 kHz and above 
Hearing loss of ≥40 dB  
at 1 kHz and above 
Muenster 
Criteria16  
<10 dB at all 
frequencies 
>10 to <20 dB at all 
frequencies 
Hearing loss  ≥4 kHz, 
>20 dB 
2a: >20 to 40 dB 
2b: >40 to 60 dB 
2c: >60 dB 
Hearing loss <4 kHz; 
>20 dB 
3a: >20 to 40 dB 
3b: >40 to 60 dB 
3c: >60 dB 
Mean hearing loss 
<4 kHz; ≥80 Db 
Chang Criteria75 < 20 dB at 1, 2, 
and 4kHz 
Hearing loss of  
1a: ≥ 40 dB at 6-12 kHz 
1b: >20 to< 40 dB at 
4kHz  
Hearing loss of  
2a: ≥ 40 dB at 4 kHz and 
above  
2b: >20 to< 40 dB below 
4kHz  
Hearing loss of ≥ 40 dB 
at 2 or 3 kHz 
Hearing loss of ≥ 40 dB  
at 1 kHz 
SIOP Boston  
Criteria18 
<20 dB hearing 
loss at all 
frequencies 
Hearing loss of >20 dB 
above 4 kHz 
Hearing loss of >20 dB at 4 - 
8 kHz 
Hearing loss of >20 dB 
at 2 - 8 kHz 
Hearing loss of > 40 dB 
 at 2 - 8 kHz 
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 Table 2: Grading scheme used for critical appraisal of evidence 
 
Grade Results Description 
++++ 
Consistent, 
generalizable 
Strong general conclusions can be drawn that are unlikely to 
change based on further research 
+++ 
Consistent, but limited 
quantity, quality or 
generalizability 
Evidence allows general conclusions, but with reduced 
confidence; further research is likely to have an important 
impact on confidence in conclusions 
++ 
Inconsistent or 
insufficient 
quantity/quality, 
encouraging 
No general conclusions can be drawn or conclusions are likely 
to change based on further research, but current evidence is 
encouraging 
+ 
Inconsistent or 
insufficient 
quantity/quality, 
discouraging 
No conclusions can be drawn or conclusions are likely to 
change based on future studies, and current evidence is 
discouraging 
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 Table 3: Grading scheme used for clinical practice guidelines  
 
Level Strength Evidence basis 
A Strong Based on strong scientific evidence; benefits clearly outweigh 
risks  
B Moderate Based on reduced confidence scientific evidence and expert 
opinion; benefits likely to outweigh risks 
C Optional Based mainly on expert opinion, for use with evidence development in a research context 
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 Table 4:  Summary of genotype-based risk stratification 
Tested Variant Genotype Frequency* Interpretation 
TPMT*3C (rs1142345) 
G/G Rare (<1%) 
Increased risk of Cisplatin-
induced Ototoxicity 
  
A/G Infrequent (0-14%) 
Increased risk of  Cisplatin-
induced Ototoxicity 
  
A/A Common (88-100%) 
Standard risk for  Cisplatin-
induced Ototoxicity 
TPMT*3B (rs1800460) 
A/A Rare (<1%) 
Increased risk of  Cisplatin-
induced Ototoxicity 
  
A/G Infrequent (0-10%) 
Increased risk of  Cisplatin-
induced Ototoxicity 
  
G/G Common (89-100%) 
Standard risk for  Cisplatin-
induced Ototoxicity 
G/G + A/A  Rare (<1%) 
Increased risk of  Cisplatin-
induced Ototoxicity 
A/G + A/G Infrequent (0-10%) 
Increased risk of Cisplatin-
induced Ototoxicity 
TPMT*3A haplotype 
(rs1142345 + 
rs1800460) 
A/A + G/G Common (89-100%) 
Standard risk for  Cisplatin-
induced Ototoxicity 
* Range of allele and haplotype frequencies for worldwide ancestries 
76,77
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